Form 8-K dated December 4, 2002
 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) December 4, 2002
 
Targeted Genetics Corporation
(Exact name of registrant as specified in charter)
 
Washington
 
0-23930
 
91-1549568
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
1100 Olive Way, Suite 100, Seattle, Washington
 
98101
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code (206) 623-7612
 
Not Applicable
(Former name or former address, if changed since last report)
 


 
Item 5.    Other Events.
 
On December 4, 2002, Targeted Genetics Corporation announced it has received notification from Celltech Group plc of its decision to terminate a collaborative agreement between the companies in support of Targeted Genetics’ cystic fibrosis program. The text of the press release is set forth in Exhibit 99.1 attached to this release and incorporated herein by this reference.
 
Item 7.    Exhibits.
 
 
(a)
 
Financial statements of business acquired.
 
Not applicable.
 
 
(b)
 
Pro forma financial information.
 
Not applicable.
 
 
(c)
 
Exhibits.
 
Exhibit No.

  
Description

99.1
  
Press Release dated December 4, 2002
 

2


 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
       
TARGETED GENETICS CORPORATION
 
Date: December 4, 2002
     
By:
 
/s/    TODD E. SIMPSON

               
Vice President, Finance and Administration and
Chief Financial Officer, Secretary and Treasurer
(Principal Financial and Accounting Officer)

3


 
EXHIBIT INDEX
 
Exhibit No.

  
Description

99.1
  
Press Release dated December 4, 2002